Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KALV SEC filings page.
This page shows KalVista Pharmaceuticals, Inc. (KALV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
KalVista remains a development-stage cash consumer, while FY2025 shows a sharp shift toward liabilities and administrative spending.
The net loss of$183M exceeded the$153M operating cash outflow, while free cash flow was nearly identical at-$153M ; earnings and cash use therefore diverged somewhat, but nearly all operating cash consumption flowed through to free cash flow.
FY2024 R&D was
Assets grew
Financial Health Signals
We are recalculating KalVista Pharmaceuticals, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
KalVista Pharmaceuticals, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
KalVista Pharmaceuticals, Inc. reported a net loss of $183.4M while operations used $152.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
KalVista Pharmaceuticals, Inc. reported an operating loss of $188.0M against $5.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
KalVista Pharmaceuticals, Inc. generated $40.9M in revenue in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
KalVista Pharmaceuticals, Inc.'s EBITDA was -$23.1M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
KalVista Pharmaceuticals, Inc. reported a net loss of $23.5M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
KalVista Pharmaceuticals, Inc. earned -$0.43 per diluted share (EPS) in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
KalVista Pharmaceuticals, Inc. recorded an outflow of $14.6M in free cash flow in Q1 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
KalVista Pharmaceuticals, Inc. held $213.8M in cash against $172.2M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Margins & Returns
KalVista Pharmaceuticals, Inc.'s gross margin was 92.4% in Q1 2026, indicating the percentage of revenue retained after direct costs.
KalVista Pharmaceuticals, Inc.'s operating margin was -57.4% in Q1 2026, reflecting core business profitability.
KalVista Pharmaceuticals, Inc.'s net profit margin was -57.5% in Q1 2026, showing the share of revenue converted to profit.
Not reported for Q1 2026.
Capital Allocation
KalVista Pharmaceuticals, Inc. invested $12.4M in research and development in Q1 2026. This represents a decrease of 53.3% from the same quarter a year earlier.
KalVista Pharmaceuticals, Inc. invested $121K in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 476.2% from the same quarter a year earlier.
Not reported for Q1 2026.
KALV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.9Mn/m | N/A | $13.7Mn/m | $1.4Mn/m | N/A | N/A | $0 | $0 |
| Cost of Revenue | $3.1M | N/A | $1.2M | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $37.8M | N/A | $12.5M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $12.4M-53.3% | N/A | $12.0M-35.8% | $15.2M-43.0% | $14.2M | $12.6M-44.1% | $18.7M-2.1% | $26.6M+37.8% |
| SG&A Expenses | $48.8M+177.2% | N/A | $46.5M+87.6% | $44.7M+153.9% | $35.5M | $30.3M+185.5% | $24.8M+132.7% | $17.6M+79.9% |
| Operating Income | -$23.4Mn/m | N/A | -$46.0Mn/m | -$59.0Mn/m | -$49.7M | -$42.9Mn/m | -$43.5Mn/m | -$44.2Mn/m |
| EBITDA | -$23.1Mn/m | N/A | N/A | -$58.8Mn/m | -$49.5M | -$42.7Mn/m | -$43.3Mn/m | -$44.0Mn/m |
| Interest Expense | $5.6M | N/A | $4.8M | $3.5M | $2.9M | N/A | N/A | N/A |
| Income Tax | $0n/m | N/A | $2.2Mn/m | $2.2Mn/m | $4.2M | $4.2M | $0 | $0 |
| Net Income | -$23.5Mn/m | N/A | -$49.5Mn/m | -$57.6Mn/m | -$51.8Mn/m | -$48.5Mn/m | -$39.1Mn/m | -$40.3Mn/m |
| EPS (Basic) | -$0.43n/m | N/A | -$0.92n/m | -$1.12n/m | -$0.98 | -$0.92 | -$0.84n/m | -$0.87n/m |
| EPS (Diluted) | -$0.43n/m | N/A | -$0.92n/m | -$1.12n/m | -$0.98 | -$0.92 | -$0.84n/m | -$0.87n/m |
| Diluted Shares (Avg) | 55M+18.1% | N/A | 54M+15.7% | 53M+15.7% | 53M | 53M | 47M+34.8% | 46M+34.3% |
KALV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'25Filing | Q1'25Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $328.9M+64.3% | $335.4M+42.5% | $339.9M+111.4% | $215.5M+7.6% | $250.8M+6.5% | $294.8M+158.7% | $160.8M+15.9% | $200.2M+24.9% |
| Current Assets | $314.2M+64.0% | $320.1M+41.9% | $325.2M+113.6% | $205.9M+7.4% | $241.7M+7.1% | $286.0M+174.7% | $152.3M+18.4% | $191.6M+27.9% |
| Cash & Equivalents | $213.8M+571.2% | $229.3M+621.5% | $243.5M+485.6% | $124.3M+290.3% | $131.6M+314.0% | $182.3M+690.8% | $41.6M-27.9% | $31.8M-35.5% |
| Short-Term Investments | $71.3M-50.0% | $70.9M-60.3% | $65.7M-30.3% | $67.2M-52.8% | $89.0M-50.2% | $86.0M+63.8% | $94.2M+107.0% | $142.4M+92.9% |
| Inventory | $4.0M | $3.4M | $458K | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $5.8M | $1.9M | $0 | $0 | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $348.6M+1708.8% | $338.1M+1073.0% | $322.9M+2525.2% | $156.1M+709.8% | $155.4M+439.1% | $130.5M+710.4% | $12.3M-49.4% | $19.3M-8.2% |
| Current Liabilities | $60.8M | $57.4M+151.5% | $45.1M | $38.4M | $45.2M+98.0% | $26.1M | N/A | N/A |
| Non-Current Liabilities | $287.8M+5668.9% | $280.7M+4567.2% | $277.9M+5843.6% | $136.3M+2633.4% | $110.2M+1732.3% | $105.3M+1582.1% | $4.7M-28.6% | $5.0M-27.3% |
| Long-Term Debt | $172.2M | $172.2M | $139.0M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$19.7M-110.9% | -$2.7M-101.2% | $17.0M-88.6% | $59.4M-67.1% | $116.8M-46.3% | $164.4M+67.9% | $148.5M+29.8% | $180.9M+29.9% |
| Retained Earnings | -$786.2Mn/m | -$762.7Mn/m | -$739.1Mn/m | -$713.3Mn/m | -$653.2Mn/m | -$580.2Mn/m | -$552.4Mn/m | -$510.2Mn/m |
Not reported in any period shown, so not listed: Goodwill.
KALV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.5Mn/m | N/A | N/A | -$54.5Mn/m | -$47.6Mn/m | -$32.7Mn/m | -$39.6Mn/m | -$40.2Mn/m |
| Depreciation & Amortization | $355K+58.5% | N/A | N/A | $252K+12.5% | $251K+14.6% | $229K+10.6% | $227K+15.2% | $224K+16.1% |
| Stock-Based Compensation | $5.1M+66.7% | N/A | N/A | $5.4M+76.9% | $3.2M | N/A | N/A | $3.0M-6.6% |
| Capital Expenditures | $121K+476.2% | N/A | N/A | $290K+1281.0% | $288K+1820.0% | $24K+26.3% | $108K+5300.0% | $21K+250.0% |
| Free Cash Flow | -$14.6Mn/m | N/A | N/A | -$54.8Mn/m | -$47.9Mn/m | -$32.7Mn/m | -$39.8Mn/m | -$40.2Mn/m |
| Investing Cash Flow | -$901K-102.4% | N/A | N/A | $21.3M-42.8% | -$3.7Mn/m | $8.5Mn/m | $48.7M+70.4% | $37.2M+89.5% |
| Financing Cash Flow | $1.5M-51.2% | N/A | N/A | $23.2M+673.7% | $2.2M-98.5% | $151.8M+53341.2% | $295K+130.5% | $3.0M+1370.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KALV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.4% | N/A | 91.0% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -57.4% | N/A | -336.1% | -4214.9% | N/A | N/A | N/A | N/A |
| Net Margin | -57.5% | N/A | -361.2% | -4114.0% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -291.1%-264.8pp | -96.9%-74.6pp | -44.4%-24.6pp | -29.5%+0.2pp | -26.3%-2.1pp | -22.3%-4.1pp |
| Return on Assets | -7.1%+13.0pp | N/A | -14.6%+9.7pp | -26.7%-6.6pp | -20.7%-2.4pp | -16.4%+9.0pp | -24.3%-4.4pp | -20.2%-4.4pp |
| Current Ratio | 5.17 | 5.58-4.3x | 7.22 | 5.37 | 5.35-4.5x | 10.95 | N/A | N/A |
| Debt-to-Equity | N/A | N/A | 8.18 | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | N/A | N/A | 19.00+18.9x | 2.63+2.5x | 1.33+1.2x | 0.79+0.6x | 0.08-0.1x | 0.110.0x |
| Asset Turnover | 0.12+0.1x | N/A | 0.040.0x | 0.010.0x | N/A | N/A | 0.00 | 0.00 |
| FCF Margin | -35.7% | N/A | N/A | -3913.7% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. KALV | FY2025 | N/A | -$183.4M | N/A | N/A | — |
| Zevra Therapeutics, Inc. ZVRA | FY2025 | $106.5M | $83.2M | 78.2% | $552.2M | 48/100 |
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $4.8B | 73/100 |
| Ionis Pharmaceuticals, Inc. IONS | FY2025 | $943.7M | -$381.4M | -40.4% | $4.6B | 70/100 |
| Viridian Therapeutics, Inc. VRDN | FY2025 | $70.8M | -$342.6M | N/A | $3.4B | 68/100 |
| NewAmsterdam Pharma Company N.V. NAMS | FY2025 | $22.5M | -$203.8M | N/A | $2.4B | 69/100 |
Where KalVista Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
No, KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $183.4M in fiscal year 2025.
KalVista Pharmaceuticals, Inc. (KALV) had EBITDA of -$187.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity of -157.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
KalVista Pharmaceuticals, Inc. (KALV) recorded an outflow of $153.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
KalVista Pharmaceuticals, Inc. (KALV) recorded an outflow of $152.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
KalVista Pharmaceuticals, Inc. (KALV) had $250.8M in total assets as of fiscal year 2025, including both current and long-term assets.
KalVista Pharmaceuticals, Inc. (KALV) invested $434K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
KalVista Pharmaceuticals, Inc. (KALV) invested $71.7M in research and development during fiscal year 2025.
KalVista Pharmaceuticals, Inc. (KALV) had a current ratio of 5.35 as of fiscal year 2025, which is generally considered healthy.
KalVista Pharmaceuticals, Inc. (KALV) had a liabilities-to-equity ratio of 1.33 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
KalVista Pharmaceuticals, Inc. (KALV) had a return on assets of -73.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, KalVista Pharmaceuticals, Inc. (KALV) held $220.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $152.9M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
KalVista Pharmaceuticals, Inc. (KALV) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $183.4M while operations used $152.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
KalVista Pharmaceuticals, Inc. (KALV) reported an operating loss of $188.0M against $5.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.